3.2. Pharmacokinetics
The pharmacokinetics of taxol has been studied extensively against lung,
breast, and ovarian cancers. Taxol is administered in patients through
the intravenous route with the use of a formulation vehicle (mainly
Cremophor® EL) for drug entrapment in micelles
(Alex et al., 2005;
Alves et al., 2018;
Shin et al., 2018). The dose of taxol
stated differently in various studies ranging from 105-270
mg/m2 in humans. The formulation vehicle not only
affects the disposition of taxol but also influences the non-linear
pharmacokinetics of taxol, specifically at a higher dosage. Plasma and
urine samples were collected for estimation of taxol concentration
through HPLC (Ishikawa et al., 2018).
Analysis of blood samples from patients depicts clearance of this drug
in approximately 3 hours, depending on the dose and vehicle used.